Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 2-9 , January 2007

Epidemiology and Pathogenesis of Esophageal Cancer

  • Rebecca S. Holmes, MD

      Affiliations

    • Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle, WA.
    • Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
    • ,
  • Thomas L. Vaughan, MD, MPH

      Affiliations

    • Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle, WA.
    • Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
    • Corresponding Author InformationAddress reprint requests to Thomas L. Vaughan, MD, MPH, Fred Hutchinson Cancer Research Center, M4-B874, 1100 Fairview Ave North, PO Box 19024, Seattle, WA 98109.

References 

  1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26:2–8
  2. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–256
  3. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450–464
  4. Lagergren J. Adenocarcinoma of oesophagus: What exactly is the size of the problem and who is at risk?. Gut. 2005;54(suppl 1):1–5
  5. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:151–159
  6. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: Scientific review. JAMA. 2002;287:1972–1981
  7. Parkin DM, Shanmugaratnam K, Sobin L, et al. Histological groups for comparative studies. 1998;International Agency for Research on Cancer Technical Report 31
  8. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1997;89:1277–1284
  9. Garavello W, Negri E, Talamini R, et al. Family history of cancer, its combination with smoking and drinking, and risk of squamous cell carcinoma of the esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:1390–1393
  10. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control. 2005;16:285–294
  11. Lee CH, Lee JM, Wu DC, et al. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer. 2005;113:475–482
  12. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113:456–463
  13. Farrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control. 2000;11:231–238
  14. Chow WH, Finkle WD, McLaughlin JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA. 1995;274:474–477
  15. Chow WH, Blot WJ, Vaughan TL. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150–155
  16. Ji BT, Chow WH, Yang G, et al. Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 1997;6:481–485
  17. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883–890
  18. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721–732
  19. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2002;11:745–752
  20. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1055–1062
  21. Navarro SA, Mayne ST, Risch HA, et al. Dietary and lifestyle patterns and risk of subtypes of esophagel and gastric cancer: factor analysis. J Nutr. 2004;134:3521S–3547S
  22. De Stefani E, Boffetta P, Deneo-Pellegrini H, et al. The role of vegetable and fruit consumption in the aetiology of squamous cell carcinoma of the oesophagus: A case-control study in Uruguay. Int J Cancer. 2005;116:130–135
  23. Gonzalez CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:345–354
  24. Jansson C, Johansson AL, Nyren O, et al. Socioeconomic factors and risk of esophageal adenocarcinoma: A nationwide Swedish case-control study. Cancer Epidemiol Biomarkers Prev. 2005;14:1754–1761
  25. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97–102
  26. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology. 2003;124:47–56
  27. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: A prospective study. Lancet Oncol. 2005;6:945–952
  28. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev. 1998;7:749–756
  29. Corley DA, Levin TR, Habel LA, et al. Barrett’s esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol. 2006;101:937–944
  30. Lagergren J, Bergstrom R, Adami HO, et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133:165–175
  31. Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006;208:233–248
  32. Ye W, Held M, Lagergren J, et al. Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 2004;96:388–396
  33. Jansson C, Plato N, Johansson AL, et al. Airborne occupational exposures and risk of oesophageal and cardia adenocarcinoma. Occup Environ Med. 2006;63:107–112
  34. Engel LS, Vaughan TL, Gammon MD, et al. Occupation and risk of esophageal and gastric cardia adenocarcinoma. Am J Ind Med. 2002;42:11–22
  35. Lindblad M, Garcia Rodriguez LA, Chandanos E, et al. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer. 2006;94:136–141
  36. Zheng W, Jin F, Devesa SS, et al. Declining incidence is greater for esophageal than gastric cancer in Shanghai, People’s Republic of China. Br J Cancer. 1993;68:978–982
  37. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888–1895
  38. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043–2053

 Supported in part by NIH: P01 CA091955 and T32CA009168

PII: S1053-4296(06)00068-3

doi: 10.1016/j.semradonc.2006.09.003

Seminars in Radiation Oncology
Volume 17, Issue 1 , Pages 2-9 , January 2007

Article Tools

* Image Usage & Resolution